Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607421 | 1.00 | NPC1 (0.51) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL10092365 | 1.00 | NPC1 (0.51) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL10144850 | 0.97 | NPC1 (0.48) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL15773620 | 0.97 | NPC1 (0.47) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL754137 | 0.91 | NPC1 (0.53) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL11910978 | 0.91 | NPC1 (0.53) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL15848405 | 0.90 | LMNA (0.53) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL203942 | 0.90 | NPC1 (0.52) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL15854471 | 0.90 | LMNA (0.53) | NPC1UCHL1KMT2AMEN1KLK7 | |
| SCHEMBL2706083 | 0.90 | NPC1 (0.52) | NPC1UCHL1KMT2AMEN1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833440-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20170157096-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9592222-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| EP-3091010-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| US-9474742-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2580209-A2 | INHIBITORS OF HCV NS5A PROTEIN | Presidio Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012123298-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | ALAM MUZAFFAR (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120040977-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPC1 122/4885UCHL1 3327/4885KMT2A 4293/4885 |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | SLC10A1, CYP2C9, UGT1A9 | NPC1 136/4885UCHL1 2358/4885KMT2A 3634/4885 |
| US-20120040977-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPC1 122/4885UCHL1 3327/4885KMT2A 4293/4885 |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | NPC1 36/4885UCHL1 3254/4885KMT2A 4475/4885 |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | FOXM1, ZC3HAV1L, C1S | NPC1 16/4885UCHL1 2208/4885KMT2A 3780/4885 |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | NPC1 76/4885UCHL1 1272/4885KMT2A 4398/4885 |
| US-20170157096-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | NPC1 893/4885UCHL1 1140/4885KMT2A 1227/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPC1 122/4885UCHL1 3327/4885KMT2A 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.